For: | Chen N, Qian MJ, Zhang RH, Gao QQ, He CC, Yao YK, Zhou JY, Zhou H. Tislelizumab-related enteritis successfully treated with adalimumab: A case report. World J Clin Cases 2022; 10(28): 10186-10192 [PMID: 36246838 DOI: 10.12998/wjcc.v10.i28.10186] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i28/10186.htm |
Number | Citing Articles |
1 |
Xuhua Huang, Linhai Zhu, Jiacong Liu, Yanye Wang, Li Yu, Simeng Wu, Wang Lv, Jian Hu. Safety and efficacy of tislelizumab plus chemotherapy as preoperative treatment in potentially resectable locally advanced non-small-cell lung cancer patients. Interdisciplinary CardioVascular and Thoracic Surgery 2024; 38(1) doi: 10.1093/icvts/ivad157
|
2 |
Shaohuan Lu, Dajian Chen, Yang Li, Qianxi Chen, Guangyi Meng, Keiko Hosohata. Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China. PLOS One 2025; 20(8): e0329464 doi: 10.1371/journal.pone.0329464
|
3 |
|
4 |
Ting-Ting Yang, Ze-Yi Wang, Pen-Ju Liu, Guang-Zhi Liu. Immune checkpoint inhibitors associated inflammatory disease of central nervous system: Case report and systemic review. Medicine 2025; 104(31): e43552 doi: 10.1097/MD.0000000000043552
|